BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34390970)

  • 1. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
    Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
    Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.
    Zhang J; Chen P; Zhu P; Zheng P; Wang T; Wang L; Xu C; Zhou J; Zhang H
    Bioorg Chem; 2020 Jun; 99():103817. PubMed ID: 32361153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
    Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
    Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia.
    Feng Z; Chen A; Shi J; Zhou D; Shi W; Qiu Q; Liu X; Huang W; Li J; Qian H; Zhang W
    Bioorg Chem; 2021 Jun; 111():104849. PubMed ID: 33798846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis and biological evaluation of imidazolopyridone derivatives as novel BRD4 inhibitors.
    Yang Y; Chen P; Zhao L; Zhang B; Xu C; Zhang H; Zhou J
    Bioorg Med Chem; 2021 Jan; 29():115857. PubMed ID: 33191086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide.
    Zhang F; Wu Z; Chen P; Zhang J; Wang T; Zhou J; Zhang H
    Bioorg Med Chem; 2020 Jan; 28(1):115228. PubMed ID: 31813613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and evaluation of novel pyridone derivatives as potent BRD4 inhibitors for the potential treatment of prostate cancer.
    Jiang W; Wang X; Shu C; Hou Q; Yang K; Wu X
    Bioorg Chem; 2022 Feb; 119():105575. PubMed ID: 34995979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
    Zhou B; Hu J; Xu F; Chen Z; Bai L; Fernandez-Salas E; Lin M; Liu L; Yang CY; Zhao Y; McEachern D; Przybranowski S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jan; 61(2):462-481. PubMed ID: 28339196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors.
    Qiao XP; Wang XT; Wang S; Mu HX; Wang QS; Chen SW
    Bioorg Med Chem; 2024 May; 106():117752. PubMed ID: 38749341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of PROTAC BCL-X
    Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
    Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
    Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein targeting chimeric molecules specific for dual bromodomain 4 (BRD4) and Polo-like kinase 1 (PLK1) proteins in acute myeloid leukemia cells.
    Mu X; Bai L; Xu Y; Wang J; Lu H
    Biochem Biophys Res Commun; 2020 Jan; 521(4):833-839. PubMed ID: 31708096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy.
    Dragovich PS; Pillow TH; Blake RA; Sadowsky JD; Adaligil E; Adhikari P; Chen J; Corr N; Dela Cruz-Chuh J; Del Rosario G; Fullerton A; Hartman SJ; Jiang F; Kaufman S; Kleinheinz T; Kozak KR; Liu L; Lu Y; Mulvihill MM; Murray JM; O'Donohue A; Rowntree RK; Sawyer WS; Staben LR; Wai J; Wang J; Wei B; Wei W; Xu Z; Yao H; Yu SF; Zhang D; Zhang H; Zhang S; Zhao Y; Zhou H; Zhu X
    J Med Chem; 2021 Mar; 64(5):2576-2607. PubMed ID: 33596073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
    Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of potent and novel dual NAMPT/BRD4 inhibitors for efficient treatment of hepatocellular carcinoma.
    Yin C; Jia S; Yang X; Wu L
    Eur J Med Chem; 2024 May; 271():116444. PubMed ID: 38691889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
    Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
    Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridine derivatives as novel dual-PLK1/BRD4 inhibitors.
    Wang NY; Xu Y; Xiao KJ; Zuo WQ; Zhu YX; Hu R; Wang WL; Shi YJ; Yu LT; Liu ZH
    Eur J Med Chem; 2020 Apr; 191():112152. PubMed ID: 32088495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 8-Methyl-pyrrolo[1,2-
    Li Z; Xiao S; Yang Y; Chen C; Lu T; Chen Z; Jiang H; Chen S; Luo C; Zhou B
    J Med Chem; 2020 Apr; 63(8):3956-3975. PubMed ID: 32208600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.